statistiche ricercatore

Continente	#
NA - Nord America	940
AS - Asia	295
EU - Europa	267
Continente sconosciuto - Info sul continente non disponibili	81
SA - Sud America	80
AF - Africa	20
Totale	1.683

Nazione	#
US - Stati Uniti d'America	920
SG - Singapore	104
IT - Italia	83
CN - Cina	70
BR - Brasile	64
HK - Hong Kong	42
RU - Federazione Russa	41
SE - Svezia	39
DE - Germania	26
VN - Vietnam	25
GB - Regno Unito	20
FR - Francia	17
FI - Finlandia	13
CA - Canada	12
IN - India	10
AR - Argentina	8
CI - Costa d'Avorio	8
BD - Bangladesh	7
JP - Giappone	6
PH - Filippine	6
IQ - Iraq	5
NL - Olanda	5
BE - Belgio	4
ID - Indonesia	4
CO - Colombia	3
EC - Ecuador	3
ES - Italia	3
SA - Arabia Saudita	3
UZ - Uzbekistan	3
ZA - Sudafrica	3
AT - Austria	2
ET - Etiopia	2
GA - Gabon	2
JM - Giamaica	2
LT - Lituania	2
PK - Pakistan	2
RS - Serbia	2
TR - Turchia	2
UA - Ucraina	2
AE - Emirati Arabi Uniti	1
AL - Albania	1
AZ - Azerbaigian	1
BY - Bielorussia	1
CH - Svizzera	1
CU - Cuba	1
DK - Danimarca	1
DZ - Algeria	1
GT - Guatemala	1
IE - Irlanda	1
IL - Israele	1
IR - Iran	1
KE - Kenya	1
LA - Repubblica Popolare Democratica del Laos	1
LB - Libano	1
MA - Marocco	1
MX - Messico	1
NI - Nicaragua	1
PL - Polonia	1
PR - Porto Rico	1
PT - Portogallo	1
PY - Paraguay	1
RO - Romania	1
SN - Senegal	1
SO - Somalia	1
SV - El Salvador	1
UY - Uruguay	1
Totale	1.602

Nome	#
Reversible Cognitive Frailty, Dementia, and All-Cause Mortality. The Italian Longitudinal Study on Aging	229
Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis	215
Daily Function as Predictor of Dementia in Cognitive Impairment, No Dementia (CIND) and Mild Cognitive Impairment (MCI): An 8-Year Follow-Up in the ILSA Study	159
The use of immunosuppressant therapy for multiple sclerosis in Italy: A multicenter retroprospective study	157
Clinical effectiveness of different natalizumab interval dosing schedules in a large Italian population of patients with multiple sclerosis	143
Detection of disability worsening in relapsing-remitting multiple sclerosis patients. A real-world roving EDSS-Expanded Disability Status Scale reference analysis from the Italian Multiple Sclerosis Register	128
PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective study	125
Data monitoring roadmap. The experience of the Italian Multiple Sclerosis and Related Disorders Register	115
Isoelectric focusing and crossed immunoelectrofocusing of cerebrospinal fluid proteins in neurological disorders	111
Incidence of amyotrophic lateral sclerosis in southern Italy: a population based study	100
null	74
null	65
null	44
null	18
Totale	1.683

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2021/2022	79	0	0	0	0	6	10	4	7	5	8	17	22
2022/2023	143	18	23	13	6	17	23	1	15	22	0	3	2
2023/2024	72	2	10	7	17	10	13	1	1	1	2	1	7
2024/2025	249	13	3	14	15	3	22	24	23	30	7	40	55
2025/2026	500	94	17	31	43	60	31	40	13	75	41	21	34
2026/2027	120	13	16	24	62	5	0	0	0	0	0	0	0
Totale													1.683